NRSN NeuroSense Therapeutics, Ltd.: Earnings growth forecast for next year
The financial stability of NeuroSense Therapeutics (NRSN) is critically tied to the success of clinical trials, which creates high volatility. The trend in consensus EPS forecasts for the coming year visualizes these risks, where 7.30 determines the current status of the parameter. Stability is maintained through the diversification of laboratories and raw material logistics, while the development vector is focused on completing the final stage of trials for the ALS drug.
Metric breakdowns and analytics for NeuroSense Therapeutics Ltd. (NRSN)
- price and consensus price forecast:
- company stock capitalization data:
- book capitalization indicators:
- issuer credit burden and liquidity indicators:
Total Debt to Capital NeuroSense Therapeutics|NRSN - Long-Term Liabilities to Capital|Short-Term Debt to Equity Ratio NeuroSense Therapeutics Ltd|NRSN - Aggregate Debt Obligations|Debt to Book Value NeuroSense Therapeutics|NRSN - Amount of Long-Term Liabilities|Company Short-Term Debts NeuroSense Therapeutics|Quick Ratio neurosense-tx.com
- net income and valuation ratios data:
NRSN - Company Net Income|Expected Profit NeuroSense Therapeutics|NRSN - Company Value to Net Income|Forward P/E Multiple NeuroSense Therapeutics Ltd|NRSN - PEG Multiple|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization NeuroSense Therapeutics|NRSN - Profit before deduction of interest, taxes, depreciation and amortization|Net earnings per share (EPS TTM) NeuroSense Therapeutics|NRSN - Net earnings per one share for the last twelve months|Year-over-year net earnings per share growth for the last 12 months neurosense-tx.com|NRSN - Earnings growth in current year|Expected earnings per share growth for next year NeuroSense Therapeutics
Fundamental company valuation:NeuroSense Therapeutics
For NeuroSense Therapeutics (NRSN), whose valuation depends on the outcomes of clinical trials for ALS drugs, the 12-month expected EPS growth chart serves as an indicator of market optimism. This metric measures the percentage change in projected earnings per share, reflecting the dynamics of discounted future earnings in analyst models. A decline in this indicator signals rising risks and a potential loss of capital investment attractiveness.
Direct competitors
Net earnings per share growth forecast for next year Biogen Corp|Neurocrine Corp (NBIX) - Consensus forecast of earnings per share growth for next year|Earnings growth forecast for next year RGC|AXSM - Expected net earnings per share growth next year|Net earnings per share growth forecast for next year ACADIA Pharmaceuticals Inc. ACAD|XENE: Projected earnings per share growth rate for next year|VKTX - Net earnings per share growth forecast for next year|Consensus forecast of earnings per share growth for next year Supernus Corp SUPN|CPRX: Earnings growth forecast for next year|Expected net earnings per share growth next year denalitherapeutics.com (DNLI)|Expected earnings per share growth for next year HRMY|BHVN: Expected earnings per share trend next year|Expected earnings per share growth for next year AMLX (Amylyx)|Projected earnings per share increase next year TRVI|Earnings growth forecast for next year PRAX (Praxis Precision Medicines)|Expected earnings per share trend next year AVXL|CeriBell - Earnings growth forecast for next year|Expected net earnings per share growth next year Prothena Corporation plc|alector.com (ALEC) - Net earnings per share growth forecast for next year|Annexon Biosciences Inc. - Expected earnings per share trend next year|OMER (Omeros Corp) - Earnings growth forecast for next year|Earnings growth forecast for next year neurogene.com|Net earnings per share growth forecast for next year AC Immune SA (ACIU)|VYGR: Net earnings per share change forecast for next year|Earnings growth forecast for next year NMRA (Neumora Therapeutics Inc)|Scilex Holding Company, Inc. (SCLX) - Expected net earnings per share growth next year|TVGN: Expected earnings per share growth for next year|ACOG - Earnings growth forecast for next year|CGTX (Cognition Therapeutics) - Expected earnings per share growth for next year|IKT: Projected earnings per share increase next year|SAVA (Cassava) - Earnings growth forecast for next year|Assertio Therapeutics (ASRT) - Consensus forecast of earnings per share growth for next year|Earnings growth forecast for next year COYA|Expected earnings per share growth for next year vistagen.com VTGN|Net earnings per share growth forecast for next year Ovid Therapeutics OVID|Consensus forecast of earnings per share growth for next year Acumen Pharmaceuticals Inc. (ABOS)|CRVO - Net earnings per share growth forecast for next year|ATHE (Alterity Therapeutics) - Projected earnings per share growth rate for next year|clene.com (CLNN) - Net earnings per share growth forecast for next year|PepGen - Expected earnings per share trend next year|Net earnings per share growth forecast for next year Jupiter Neurosciences Inc|Relmada Therapeutics Inc (RLMD) - Consensus forecast of earnings per share growth for next year|Net earnings per share growth forecast for next year Annovis Bio Corp (ANVS)|gracetx.com - Projected earnings per share growth rate for next year|Net earnings per share growth forecast for next year Firefly Neuroscience, Inc AIFF|KLTO: Projected earnings per share growth rate for next year|Reviva Pharmaceuticals Holdings, Inc. - Earnings growth forecast for next year|Expected net earnings per share growth next year MetaVia Inc|NRXS (NeurAxis, Inc) - Expected earnings per share growth for next year|Helius Medical Technologies (HSDT) - Earnings growth forecast for next year|Net earnings per share growth forecast for next year Passage Bio Inc.|NEUP: Expected earnings per share trend next year|Net earnings per share growth forecast for next year Minerva Neurosciences, Inc. (NERV)|ATHA - Expected net earnings per share growth next year|Net earnings per share growth forecast for next year Addex Therapeutics, Ltd. ADXN|ALZN: Projected earnings per share growth rate for next year|Cyclerion - Earnings growth forecast for next year|Expected net earnings per share growth next year Protagenic Therapeutics|KTTA (pasitheaclinics.com) - Expected earnings per share growth for next year|Cortigent (CRGT) - Earnings growth forecast for next year|Net earnings per share growth forecast for next year Avenue Therapeutics, Inc|BCLI: Expected earnings per share trend next year|Net earnings per share growth forecast for next year Cara Therapeutics, Inc. (CARA)|CHRO - Expected net earnings per share growth next year|Net earnings per share growth forecast for next year Eliem Therapeutics Inc. ELYM|Consensus forecast of earnings per share growth for next year Intra-Cellular Therapies Inc. (ITCI)|Longboard Pharma - Earnings growth forecast for next year|Expected net earnings per share growth next year Marinus Pharma|NKGen Biotech, Inc. (NKGN) - Net earnings per share growth forecast for next year|Projected earnings per share growth rate for next year NRBO|Net earnings per share growth forecast for next year Sage Therapeutics|Synaptogenix Inc. (SNPX) - Consensus forecast of earnings per share growth for next year|Earnings growth forecast for next year TRVN|VIGL - Expected net earnings per share growth next year|Anew Medical - Expected earnings per share growth for next year|Expected earnings per share trend next year CERE
